Jens Henrik Norum
- Senior scientist; PhD
- +47 22 78 14 83
Publications 2021
Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
Sci Rep, 11 (1), 6317
DOI 10.1038/s41598-021-85613-8
Publications 2020
Re-definition of claudin-low as a breast cancer phenotype
Nat. Commun., 11 (1), 1787
DOI 10.1038/s41467-020-15574-5
GLI1-induced mammary gland tumours are transplantable and maintain major molecular features
Int. J. Cancer, 146 (4), 1125-1138
DOI 10.1002/ijc.32522
Publications 2019
Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers
Breast Cancer Res., 21, 85
DOI 10.1186/s13058-019-1170-8
Publications 2018
The tankyrase inhibitor G007-LK inhibits small intestine LGR5(+) stem cell proliferation without altering tissue morphology
Biol. Res., 51, 3
DOI 10.1186/s40659-017-0151-6
Publications 2017
Interrogating open issues in cancer precision medicine with patient-derived xenografts
Nat. Rev. Cancer, 17 (4), 254-268
DOI 10.1038/nrc.2016.140
Publications 2015
A conditional transgenic mouse line for targeted expression of the stem cell marker LGR5
Dev. Biol., 404 (2), 35-48
DOI 10.1016/j.ydbio.2015.05.002
Publications 2014
Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy
Br. J. Surg., 101 (8), 925-938
DOI 10.1002/bjs.9562
Publications 2008
An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells
Mol. Cancer Res., 6 (10), 1630-1638
DOI 10.1158/1541-7786.MCR-07-2172
Publications 2007
Epac- and Rap-independent ERK1/2 phosphorylation induced by G(s)-coupled receptor stimulation in HEK293 cells
FEBS Lett., 581 (1), 15-20
DOI 10.1016/j.febslet.2006.11.069